Structure Therapeutics Inc Insider Trading
Every director, officer and 10% holder of Structure Therapeutics Inc has to report each trade in its stock within two business days of making it. This is those filings.
GPCR on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Crespo Blas CollCHIEF MEDICAL OFFICER2026-09-214K shat $36.15 | Salederivative10b5-1 plan | $144.9K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-09-011.3K shat $45.86 | Salederivative10b5-1 plan | $59.6K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-09-014.5K shat $47.20 | Salederivative10b5-1 plan | $214.3K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-09-01100 shat $47.83 | Salederivative10b5-1 plan | $4.8K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-08-183K shat $53.13 | Salederivative10b5-1 plan | $160.5K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-08-18519 shat $54.20 | Salederivative10b5-1 plan | $28.1K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-08-18400 shat $55.05 | Salederivative10b5-1 plan | $22K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-08-043.1K shat $49.29 | Salederivative10b5-1 plan | $152.8K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-08-04839 shat $50.03 | Salederivative10b5-1 plan | $42K |
| FMR LLC10% owner2026-07-221.4K shat $50.07 | Salederivative | $68.4K |
| FMR LLC10% owner2026-07-2216.1K shat $50.07 | Salederivative | $805.4K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-146.3K shat $50.80 | Salederivative10b5-1 plan | $318.9K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-141.6K shat $51.71 | Salederivative10b5-1 plan | $82.7K |
| Xichen LinCHIEF SCIENTIFIC OFFICER2026-06-257.9K shat $49.08 | Salederivative10b5-1 plan | $386.6K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on GPCR
Follow Structure Therapeutics Inc (GPCR) by email
New trades in Structure Therapeutics Inc (GPCR) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.